Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 399 for:    sodium phosphate

EryDex Pharmacokinetics in Healthy Volunteers (EryDex)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01925859
Recruitment Status : Completed
First Posted : August 20, 2013
Last Update Posted : June 1, 2015
Sponsor:
Information provided by (Responsible Party):
Erydel

Brief Summary:
To compare the pharmacokinetic properties of two different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of dexamethasone.

Condition or disease Intervention/treatment Phase
Healthy Drug: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics Study to Measure Plasma Concentrations of Dexamethasone Following EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) Infusion in Healthy Volunteers
Study Start Date : June 2013
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013


Arm Intervention/treatment
Experimental: EryDex System
erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
Drug: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
Other Name: EryDex System (dexamethasone sodium phosphate encapsulated erythrocytes)




Primary Outcome Measures :
  1. Pharmacokinetic comparison of two different doses of EryDex in two independent groups [ Time Frame: 42 days after infusion ]
    • To compare the pharmacokinetic (PK) properties of 2 different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of dexamethasone.


Secondary Outcome Measures :
  1. Evaluation of safety and tolerability of a single infusion of EryDex administered in two different doses in healthy volunteers [ Time Frame: 84 days after infusion ]
    • To evaluate the safety and tolerability of a single infusion of EryDex, administered at 2 different doses in healthy volunteers, based on the following: Treatment-Emergent Adverse Events (TEAEs), Serious AEs (SAEs), laboratory parameters, vital signs, ECGs and physical examination findings.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Ages 18-55 years, inclusive.
  2. If female, the subject is not pregnant or lactating, and has negative serum pregnancy tests at Screening and Baseline (check-in).
  3. If female of childbearing potential*, the subject agrees not to donate ova and to use one of the following methods of contraception from the time of signing the informed consent until 2 months after infusion.

    1. Cap or diaphragm with spermicidal cream or jelly + male condom and spermicide.
    2. Hormonal contraceptives (oral, implant, injection or patch) + male condom and spermicide.
    3. Intrauterine devices + male condom or spermicide.
    4. Vaginal ring + male condom and spermicide.

      • Non-childbearing potential is defined as surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation), hysterectomy at least 3 months before the start of the study, or postmenopausal (defined as continuous amenorrhea for at least 2 years).
  4. If male, the subject agrees to not donate sperm and to use barrier contraception (e.g., condom with spermicidal cream or jelly) from the time of signing the informed consent until 2 months after infusion.
  5. Physically and mentally healthy, as confirmed by medical history, physical examination, vital signs, clinical laboratory tests, and ECG.
  6. The subject has a body weight of at least 45 kg and a body mass index of ≤ 30.
  7. Written informed consent to participate was obtained from the subject.
  8. Ability to understand the aims of the trial and comply with the study procedures.

Exclusion Criteria:

  • General

    1. Females that are of childbearing potential, pregnant, or are breast-feeding. Women of childbearing potential using two forms of birth control (e.g. barrier and hormonal) will be eligible.
    2. Loss/removal of 500 mL or more of blood within the past 4 weeks.
    3. A disability that may prevent the subject from completing all study requirements.
    4. Noncompliance with the study requirements. Medical History
    5. Current or previous neoplastic disease.
    6. History of any impairment of the immunological system.
    7. History of drug or alcohol abuse (within past 5 years).
    8. A current diagnosis of severe or unstable cardiovascular disease;
    9. Any history or current evidence of a cardiac illness as determined by the investigator;
    10. History or current diagnosis of a psychiatric illness (DSM-IV-TR Axis I diagnosis) or neurodegenerative disorder.
    11. Smoker; currently or at any time in the last 6 months.
    12. Hemoglobinopathy or G6PD deficiency.
    13. History of recurrent or chronic infections, including Staphylococcus or methicillin-resistant Staphylococcus aureus (MRSA).
    14. History of positive tuberculosis skin test (PPD test). Current Medical Status
    15. Have any other significant disease or condition that in the Investigator's opinion would put the subject at risk for participating in the trial.
    16. Vital signs outside the following ranges:

      1. Systolic blood pressure <90 or >140 mmHg
      2. Diastolic blood pressure <50 or >90 mmHg
      3. Pulse <50 or >90 bpm. Patients with pulse rates <50 that are otherwise healthy will be eligible for the trial if approved by the Sponsor.
    17. Any clinically significant ECG abnormality, including a disorder of rate, rhythm, or conduction, or other morphological changes.
    18. Any clinically significant abnormality on standard laboratory examinations (hematology, biochemistry, urinalysis), as determined by the Investigator, in consultation with the Sponsor.
    19. History of hepatitis B and/or C, and/or positive serology results, which indicate the presence of hepatitis B and/or C (Hepatitis B surface antigen and/or antibody to Hepatitis C).
    20. Positive results from the HIV serology.
    21. Positive results of the drug and alcohol tests at screening and/or check-in at the unit. Alcohol intake should be limited to 2 drinks per day during the 2 weeks prior to dosing; alcohol consumption will be prohibited from the time o
    22. Clinically significant abnormal serum cortisol levels (below normal range or >1.5x ULN) at screening.

      Prior/Concomitant Medication

    23. Any previous steroid consumption within 4 weeks before Baseline.
    24. Chronic condition or prior allergic reaction representing a contraindication to the use of steroid drugs.
    25. Have participated in any other trial with an investigational drug and received a dose within 30 days or 10 half-lives (whichever is greater) from the start of the Screening Period.
    26. Requirement for any prescription or over-the-counter (OTC) medication, other than hormonal birth control or occasional use of acetaminophen, that cannot be discontinued during screening, at least one week before Baseline, and throughout the 42-day study period.

      f admittance on Day -1 through to the final safety evaluations on Day 42.

    27. A drug or treatment known to cause major organ system toxicity during the past year.
    28. Caffeine-containing products in excess of the equivalent of 2 cups of coffee per day during the 2 weeks prior to dosing and through to the final safety evaluations on Day 42.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01925859


Locations
Layout table for location information
United States, Maryland
SNBL Clinical Pharmacology Center
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Erydel
Investigators
Layout table for investigator information
Principal Investigator: Mohamed Al-Ibrahim, MD SNBL Pharmacology Center

Layout table for additonal information
Responsible Party: Erydel
ClinicalTrials.gov Identifier: NCT01925859     History of Changes
Other Study ID Numbers: IED-PK01-2013
First Posted: August 20, 2013    Key Record Dates
Last Update Posted: June 1, 2015
Last Verified: December 2014

Keywords provided by Erydel:
Pharmacokinetic analysis
EryDex

Additional relevant MeSH terms:
Layout table for MeSH terms
Dexamethasone 21-phosphate
Dexamethasone
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action